Adimmune Corporation (4142.TW) TAI
17.20
+0(+0.00%)
Currency In TWD
- General
- Statistics
- Historical Data
- Profile
- Financials
17.20
+0(+0.00%)
Currency In TWD
Address
No. 3, Tanxing Road
Taichung, 427003
Taiwan (Province of China)
Phone
886 4 2538 1220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
564
First IPO Date
May 03, 2012
| Name | Title | Pay | Year Born |
| Chi-Hsien Chan | Chief Executive Officer & Chairman | 24.04M | N/A |
| Chin-I Chiu | Vice President of Quality Assurance Department | 5.13M | N/A |
| Fei Pan | Chief Legal Officer & General Counsel | 5.25M | N/A |
| Chin-Chuan Chang | Chief Operating Officer and Vice President of R&D | 5.34M | N/A |
| Zhe Wei Zhang | Executive Vice GM | 0 | N/A |
| Cheng Liu Churg | Acting R&D Officer | 0 | N/A |
| Chih-Hsiang Leng | Head of R&D Division | 0 | N/A |
| Li-Ya Tang | Director of Administration Center | 0 | N/A |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.